BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.83 USD | -0.91% |
|
-1.80% | -15.13% |
Presentation Operator MessageOperator (Operator)Thank you for joining BioMarin's second quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
81.83
USD
Average target price
110
USD
Spread / Average Target
+34.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.13% | 15.54B | |
| -3.35% | 88.91B | |
| +4.08% | 41.25B | |
| -15.09% | 31.99B | |
| +52.98% | 24.73B | |
| -8.63% | 12.05B | |
| -40.39% | 12.07B | |
| +6.22% | 8.84B | |
| -5.15% | 8.3B | |
| -6.45% | 7.07B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc., Q2 2023 Earnings Call, Jul 31, 2023